Cluster Transfronterizo Biotecnológico

Oncostellae

Description

Oncostellae is a biotechnology company that develops innovative small molecules for use as drugs in oncology and inflammatory/automotive diseases.

The company was founded in 2013 by a team of pharmacists with a common track record in drug discovery, who bring together the expertise and network of collaborators needed to develop clinical candidates from conception through Phase I/II, and then license them to established pharmaceutical companies.

Areas/Lines R+D+i

Focused on drug development, medical chemistry and pharmacology

Most important R+D+i projects

All developments have taken place from internal medical chemistry programs and are based on new proprietary chemical entities (NCEs) (composition of matter, priority filings in 2017).

OST-122, the company’s most advanced compound, is an oral, gastrointestinal tract restricted Jak3/Tyk2-Ark5 inhibitor that has already completed Phase I studies in healthy volunteers. Preparation for a proof-of-concept study in patients with ulcerative colitis is currently underway.

The design of safer and organ-selective JAK inhibitors is being explored in other programs aimed at the local treatment of inflammatory/automotive diseases in other tissues such as lung, skin and eyes.

Current PIPELINE:

OST-122: Oral Jak3/Tyk2-Ark5 inhibitor of restricted action to the gastrointestinal tract (inflammatory bowel disease), in preparation of proof of concept studies in patients with ulcerative colitis.
OST-499: Oral non-steroidal GR/PR antagonist (castration-resistant prostate cancer, immuno-oncology), in preclinical development.
OST-476: Inhaled Jak3/Tyk2 selective action lung inhibitor (COPD, asthma), in advanced compound optimization phase.